Legal developments and practical compliance guidance for RUO sellers, clinics, wellness centers, chiropractors, pharmacies, compounders, and other peptide businesses.
Latest articles
-
FDA Peptide Warning Letters: Why Reconstitution Supplies and Website Claims Matter
FDA’s August 24 warning letters show why peptide product claims and accompanying reconstitution supplies should be reviewed together. Learn what the agency documented and how businesses can assess their entire storefront.
-
Paradigm Peptides Sentencing: Why Online Claims and Supplier Records Matter
The Paradigm Peptides defendants received 70- and 16-month prison sentences after guilty pleas. The case shows why online regulatory claims, supplier records and lot-level testing documentation require careful review.
-
FDA’s Updated Import Alert: What Peptide Businesses Should Check Before Buying GLP-1 Ingredients
FDA’s September 21, 2026 import-alert update highlights checks for foreign GLP-1 ingredients. Learn what Green List status means, how detention differs from criminal enforcement, and when to review suppliers with counsel.
-
Peptide Compounding After the Empower Warning: Why Patient-Specific Records Matter
FDA’s September 18 Empower Pharmacy warning letter questions vitamin-added GLP-1 formulations and repeated prescribing statements. Learn why patient-specific records and a review of prescribing workflows matter for peptide businesses.
-
Counterfeit Ozempic Charges: Supply-Chain Lessons for Peptide Businesses
FDA’s September 29 announcement of counterfeit Ozempic charges highlights supplier verification, product tracing, and response planning for peptide businesses. Learn what the allegations mean and what to review.
-
Apex Federal Searches: What Peptide Businesses Should Know
Federal agents searched Apex-linked properties on September 23. Here is what local reporting confirms, what remains unknown about peptides and money laundering, and what businesses should review now.
-
Why Every Peptide Business Needs a Legal Compliance Review Now
Recent FDA warning letters and retatrutide litigation highlight why RUO sellers, clinics, wellness centers, chiropractors, pharmacies, and compounders should obtain a review of their marketing, sourcing, and business practices.